The effectiveness and safety of methotrexate in the intervention of osteoarthritis: A systematic review and meta-analysis of randomized controlled trials

Эффективность и безопасность метотрексата при лечении остеоартрита: систематический обзор и метаанализ рандомизированных контролируемых исследований
Liuting Zeng, Kailin Yang, Lifei Wan, Qianyue Yang, Lingyun Sun
2025-10-10

WOMAC scoremethotrexateosteoarthritisrandomized controlled trialssystematic review and meta-analysis
BACKGROUND: Osteoarthritis (OA) is a prevalent chronic joint disorder among middle-aged and older adults, characterized by progressive cartilage degeneration, subchondral bone remodeling, and osteophyte formation, leading to joint pain, stiffness, dysfunction, and reduced quality of life. With the global aging population, OA imposes a growing socioeconomic burden, yet no disease-modifying therapy is currently available-particularly for moderate-to-severe stages. Emerging evidence implicates synovial inflammation as a central contributor to OA symptoms and progression, raising interest in methotrexate (MTX), a well-established, low-dose anti-inflammatory agent used safely in rheumatoid arthritis. Preliminary studies suggest MTX may alleviate OA-related pain, but findings from randomized controlled trials (RCTs) have been inconsistent and limited in number. Given recent new RCTs and the heterogeneity of existing outcomes, an updated systematic review and meta-analysis is urgently needed to clarify the efficacy and safety of MTX in OA and inform future clinical trial design. METHODS: PubMed, ClinicalTrials, Web of Science, Cochrane Library and other databases were searched to find randomized controlled trials (RCT) of MTX treatment of OA. Methodological quality was assessed using the Cochrane "risk of bias" assessment tool, and the meta-analysis was conducted using Review Manager (RevMan) version 5.3 (The Cochrane Collaboration, London, UK). RESULTS: Fifteen RCTs involving 1591 participants were included in this review. The meta-analysis results showed that the ineffective rate in the experimental group was lower [RR: 0.40 (0.24, 0.67), P = .004]; the VAS in the experimental group was lower [WMD: -0.66 (-1.08, -0.24), P = .002]; the WOMAC score-stiffness in the experimental group was lower [WMD: -0.72 (-1.04, -0.41), P < .00001]; the WOMAC score-function in the experimental group was lower [WMD: -7.72 (-13.56, -1.87), P = .01]. The adverse events in the experimental group were not statistically significant compared with the control group [RR: 1.04 (0.77, 1.42), P = .78]. CONCLUSION: MTX demonstrates potential in effectively alleviating pain, improving joint function, and slowing disease progression in patients with OA. Its safety profile is comparable to that of control treatments, making it a viable and reliable therapeutic option worthy of broader clinical application.
1
A systematic review and meta-analysis included 15 randomized controlled trials involving 1,591 participants with osteoarthritis.
2
Methotrexate improved WOMAC stiffness and function scores, with WMDs of −0.72 (P < .00001) and −7.72 (P = .01), respectively.
3
Methotrexate improved pain, with lower visual analog scale scores than controls (WMD −0.66, 95% CI −1.08 to −0.24; P = .002).
4
Methotrexate reduced treatment ineffectiveness compared with control interventions (RR 0.40, 95% CI 0.24–0.67; P = .004).
5
The abstract reports assessment of adverse events, but the provided text does not state the corresponding safety results.

Methotrexate treatment in patients with osteoarthritis

The efficacy and safety of methotrexate, including effects on pain, stiffness, physical function, treatment response, and adverse events

Publication Details
Publication Date
2025-10-10
Journal
Publisher
ISSN
Cited by
1
Access Type
Author Information
Authors
Liuting Zeng
Kailin Yang
Lifei Wan
Qianyue Yang
Lingyun Sun
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%